Breaking News
Get 50% Off 0
📌 New AI-picked stocks coming soon. 3 picks from last month are already up +30%...
Get early access
Close

TuHURA Biosciences Inc (HURA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow TuHURA Biosciences's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.6800 -0.1000    -3.60%
29/07 - Closed. Currency in USD
After Hours
2.7300
+0.0500
+1.8657%
21:45:37 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 164,663
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 2.6400 - 2.7800
TuHURA Biosciences 2.6800 -0.1000 -3.60%

TuHURA Biosciences Inc Company Profile

 
Get an in-depth profile of TuHURA Biosciences Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

19

Equity Type

ORD

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company’s lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-specific antibody-peptide conjugates and antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.

Contact Information

Address 10500 University Center Drive Suite 110
Tampa, 33612
United States
Phone 813 875 6600
Fax -

Top Executives

Name Age Since Title
Robert E. Hoffman 59 2024 Director
James A. Bianco 68 2021 President, CEO & Director
Alan F. List 70 2024 Independent Director
Craig L. Tendler - 2025 Independent Director
James S. J. Manuso 76 2024 Independent Chairman of the Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

HURA Comments

Write your thoughts about TuHURA Biosciences Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email